ALTEOGEN Past Earnings Performance
Past criteria checks 2/6
ALTEOGEN has been growing earnings at an average annual rate of 16.4%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 28.1% per year. ALTEOGEN's return on equity is 10%, and it has net margins of 21.1%.
Key information
16.4%
Earnings growth rate
16.8%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 28.1% |
| Return on equity | 10.0% |
| Net Margin | 21.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution
May 25
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?
Feb 29ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability
Apr 13Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Feb 18
Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?
Dec 27Revenue & Expenses Breakdown
How ALTEOGEN makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 121,087 | 25,542 | 13,955 | 23,635 |
| 31 Dec 23 | 96,523 | -3,372 | 14,468 | 25,306 |
| 30 Sep 23 | 85,036 | 6,454 | 14,421 | 21,286 |
| 30 Jun 23 | 69,154 | 7,856 | 15,083 | 17,695 |
| 31 Mar 23 | 32,199 | -21,798 | 14,927 | 22,559 |
| 31 Dec 22 | 28,806 | -8,146 | 14,234 | 18,660 |
| 30 Sep 22 | 32,292 | 1,367 | 14,412 | 12,422 |
| 30 Jun 22 | 33,065 | -223 | 15,107 | 4,731 |
| 31 Mar 22 | 33,807 | -1,243 | 22,709 | 1,165 |
| 31 Dec 21 | 38,746 | -6,275 | 12,713 | 7,480 |
| 30 Sep 21 | 29,498 | -38,971 | 12,251 | 14,481 |
| 30 Jun 21 | 37,316 | -26,975 | 12,134 | 14,481 |
| 31 Mar 21 | 44,433 | -17,748 | 3,179 | 15,350 |
| 31 Dec 20 | 42,426 | -15,822 | 10,537 | 7,691 |
| 30 Sep 20 | 51,935 | 15,424 | 9,513 | 6,308 |
| 30 Jun 20 | 43,420 | 9,040 | 7,886 | 6,308 |
| 31 Mar 20 | 35,242 | 5,001 | 6,966 | 5,566 |
| 31 Dec 19 | 29,229 | -705 | 6,418 | 6,457 |
| 30 Sep 19 | 18,012 | -7,900 | 5,647 | 5,671 |
| 30 Jun 19 | 15,796 | -8,574 | 6,110 | 5,671 |
| 31 Mar 19 | 13,473 | -8,078 | 3,978 | 6,718 |
| 31 Dec 18 | 13,703 | -6,872 | 3,355 | 5,962 |
| 30 Sep 18 | 13,079 | -11,776 | 2,615 | 7,983 |
| 30 Jun 18 | 12,610 | -9,945 | 794 | 7,983 |
| 31 Mar 18 | 11,788 | -10,332 | 1,790 | 6,394 |
| 31 Dec 17 | 12,104 | -7,449 | 2,316 | 4,654 |
| 30 Sep 17 | 11,815 | -2,837 | 2,305 | 3,631 |
| 30 Jun 17 | 11,567 | -2,871 | 2,314 | 3,631 |
| 31 Mar 17 | 10,569 | -1,961 | 2,257 | 3,765 |
| 31 Dec 16 | 6,844 | -3,587 | 1,879 | 3,976 |
| 30 Sep 16 | 6,088 | -1,481 | 1,603 | 3,323 |
| 30 Jun 16 | 4,213 | -201 | 891 | 3,323 |
| 31 Mar 16 | 3,634 | -136 | 599 | 2,719 |
| 31 Dec 15 | 4,727 | 1,208 | 1,333 | 1,947 |
| 30 Sep 15 | 4,585 | 337 | 1,375 | 1,982 |
| 30 Jun 15 | 5,686 | 320 | 1,207 | 1,982 |
| 31 Mar 15 | 6,874 | 1,209 | 1,411 | 1,906 |
| 31 Dec 14 | 7,043 | 931 | 1,285 | 1,837 |
| 30 Sep 14 | 6,753 | 1,158 | 1,294 | 1,534 |
| 30 Jun 14 | 6,257 | 1,224 | 991 | 1,791 |
| 31 Mar 14 | 6,003 | 1,434 | 747 | 1,692 |
| 31 Dec 13 | 5,527 | 1,606 | 1,159 | 1,043 |
Quality Earnings: A196170 has a high level of non-cash earnings.
Growing Profit Margin: A196170 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A196170 has become profitable over the past 5 years, growing earnings by 16.4% per year.
Accelerating Growth: A196170 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A196170 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: A196170's Return on Equity (10%) is considered low.